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Ischemic preconditioning (IPC) or postconditioning (Ipost) is proved to eﬃciently prevent ischemia/reperfusion injuries. Mortal-
ity of diabetic patients with acute myocardial infarction was found to be 2–6 folds higher than that of non-diabetic patients with
same myocardial infarction, which may be in part due to diabetic inhibition of IPC- and Ipost-mediated protective mechanisms.
Both IPC- and Ipost-mediated myocardial protection is predominantly mediated by stimulating PI3K/Akt and associated GSK-3β
pathway while diabetes-mediated pathogenic eﬀects are found to be mediated by inhibiting PI3K/Akt and associated GSK-3β
pathway. Therefore, this review brieﬂy introduced the general features of IPC- and Ipost-mediated myocardial protection and the
general pathogenic eﬀects of diabetes on the myocardium. We have collected experimental evidence that indicates the diabetic
inhibition of IPC- and Ipost-mediated myocardial protection. Increasing evidence implies that diabetic inhibition of IPC- and
Ipost-mediated myocardial protection may be mediated by inhibiting PI3K/Akt and associated GSK-3β pathway. Therefore any
strategy to activate PI3K/Akt and associated GSK-3β pathway to release the diabetic inhibition of both IPC and Ipost-mediated
myocardial protection may provide the protective eﬀect against ischemia/reperfusion injuries.
1.Introduction
Acute myocardial infarction (AMI) is a worldwide problem
that threatens the human’s health both in the developed
and developing countries. AMI is often induced by the
complete thrombotic occlusion of coronary arteries at the
site of a ruptured atherosclerotic plaque. Prompt reperfusion
is a deﬁnitive treatment to salvage ischemic myocardium
from inevitable death. Experimental and clinical investi-
gations suggest that although reperfusion can salvage the
ischemic myocardium, it can also induce side eﬀect, called
as ischemia/reperfusion injuries. It is appreciated now that
lethal myocardial injury caused by ischemia/reperfusion
accountsforupto50%oftheﬁnalinfarctsizeofamyocardial
infarct [1].
Myocardial ischemia/reperfusion injury is a complex
pathophysiological event, resulting in serious acute and
chronic myocardial damage. It is characterized by a cas-
cade of acutely initiated local inﬂammatory responses,
metabolic disorder, and cell death, leading to myocardial
ultrastructural changes and remodeling and subsequently
myocardial systolic and diastolic dysfunction [2–4]. Myocar-
dial ischemia/reperfusion injury also induces ventricular
arrhythmias, resulting in circulation collapse and sudden
death [5, 6].
Numerous studies have demonstrated that inﬂammation
following ischemia/reperfusion injury exacerbates myocar-
dial injury [4, 7]. In addition to inﬂammation, profound
alterationsinmyocardialmetabolism,suchasthedisarrange-
ment of glycolysis and fatty acid oxidation, also signiﬁcantly2 Experimental Diabetes Research
impact on the cell integrity and functional recovery of the
myocardium [8]. Evidence from previous studies suggests
that reactive oxygen or nitrogen species (ROS or RNS),
including superoxide radicals, hydrogen peroxide, hydroxyl
radicals, singlet oxygen, nitric oxide, and peroxynitrite
play major contribution to myocardial ischemia/reperfusion
injury [9, 10]. These ROS and/or RNSs, which are formed
within the ischemic myocardial cells and in the ﬁrst few
moments of reperfusion, are known to be cytotoxic to
surrounding cells. In addition, it is also widely accepted
that apoptotic cell death is involved in the development of
ischemic myocardial damage [11]. Therefore, how to protect
the ischemic myocardium from reperfusion injury is the
key issue for cardiologist and cardiovascular physicians. This
review brieﬂy overviews the status of ischemic precondition-
ing (IPC) and ischemic postconditioning (Ipost) with an
emphasis of the diabetic eﬀects on the myocardial protection
of IPC and Ipost as well as possible mechanisms.
2. Ischemic Preconditioning,Postconditioning,
andTheir MyocardialProtectiveMechanisms
2.1. Ischemic Preconditioning and Its Myocardial Protection.
Murry et al. (1986) ﬁrst found the potent myocardial pro-
tection by preconditioning the ischemic myocardium when
they gave transient and repeat ischemia and reperfusion
before the occlusion of the coronary artery in dog heart
[12]. They found that multiple brief ischemic episodes
actually protected the myocardium from a subsequent
sustained ischemic insult. They called this protective eﬀect
as IPC (Figure 1). IPC is a well-described adaptive response
by which brief exposure to ischemia/reperfusion before
sustained ischemia markedly enhances the ability of the
myocardium to withstand a subsequent ischemic insult [13].
The protection of IPC is displayed as the reduction of
ischemia/reperfusion-induced infarct size, arrhythmia, and
the improvement of contractile and diastolic function of the
myocardial muscle. Consequently, many studies indicated
that IPC was an endogenous protection for AMI, by induc-
ing phosphatidylinositol 3-kinase (PI3K), protein kinase C
(PKC) and JAK/STAT pathways [12, 14–17]. Among these,
the activation of PI3K/protein kinase B (Akt) pathway was
found to play an important role in protecting myocardial
ischemia/reperfusion injury [15, 16, 18]. The PI3K/Akt
pathway aﬀects cell survival by a variety of substrates,
including apoptotic proteins, endothelial nitric oxide syn-
thase (eNOS), and PKC [19, 20]. More recent interest
has focused on glycogen synthase kinase-3β (GSK-3β)a s
a distal kinase, phosphorylated (and hence inactivated) by
other kinases, including Akt and p42/p44 MAPK/ERK [21,
22]. GSK-3β is a multifunctional Ser/Thr kinase that plays
important roles in necrosis and apoptosis of cardiomyocytes.
GSK-3 activity has been associated with many cell processes,
including the regulation of multiple transcription factors,
the Wnt pathway, nuclear factor κB, endoplasmic reticulum
stress, embryogenesis, apoptosis and cell survival, cell cycle
progression, cell migration, and so on [23, 24].
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Figure 1: The illustration of IPC and Ipost. IPC means that
transient and repeat ischemia and reperfusions were given before
the occlusion of the coronary artery. Ipost means that transient and
repeat ischemia and reperfusions were given after the occlusion and
before the reperfusion of coronary artery.
IPC produces myocardial protection by phosphorylating
and consequently inactivating GSK-3β [21]. However, since
ischemic event is unpredictable and IPC is also invasive,
myocardial protection by IPC is diﬃcult to be used in clinics.
In this review, we do not introduce the detail status of
IPC myocardial protection and possible mechanisms since
these issues have been extensively discussed in a few recent
excellent reviews [25–28].
2.2. Ischemic Postconditioning and Its Myocardial Protection.
The Ipost came into notice of Zhao et al. (2003) when
theymovedthetransientandrepeatischemia/reperfusionsto
after the occlusion and before the reperfusion, as illustrated
in Figure 1 [2]. Subsequently, a lot of researchers reported
the same protective eﬀects [29, 30]. They found that cycles
of brief reperfusion and ischemia performed immediately
at the onset of reperfusion following a prolonged ischemic
insult markedly limited reperfusion injury. Like IPC, the
Ipost is also a powerful approach to protect the ischemic
myocardium from reperfusion-induced damage [31–33]. In
clinics, with the development of percutaneous coronary
intervention emerged as an exciting innovative treatment
strategy, it makes Ipost possible to intervene AMI. A recent
analysis of data on infarct size and ischemic zone size
indicatesthatcurrentreperfusiontherapysalvagesmorethan
50% of the ischemic myocardium in approximately half of
the patients with AMI [34].
It has been supported by several studies that Ipost
protected the myocardium against the detrimental eﬀects
of lethal myocardial reperfusion injury by limiting oxida-
tive stress, reducing calcium accumulation, maintaining
endothelial function, and reducing inﬂammation [35–37].
Subsequent studies have identiﬁed a number of signaling
pathways which are activated by Ipost, and involve in the
myocardial protection of Ipost. Among these pathways,
reperfusion injury salvage kinase (RISK) pathway was the
ﬁrst signaling cascade to be linked to Ipost [21], which
showed that Ipost was capable of recruiting prosurvival
signal cascades including PI3K/Akt, PKC, GSK-3β,e N O S ,
and guanylyl-cyclase, as disclosed for the mechanisms of IPC
myocardial protection (see the above discussion).
The discovery of IPC and Ipost, including pharmaco-
logical preconditioning and postconditioning, as the two
major forms of endogenously protective mechanisms in theExperimental Diabetes Research 3
myocardium have encouraged us to explore new ways to
protectthemyocardiumfromischemia/reperfusionandhave
enriched our knowledge of the molecular basis of injury and
survival during ischemia/reperfusion [13]. In both IPC- and
Ipost-mediated myocardial protections, PI3K/Akt activation
is considered as an initial step that induces phosphory-
lation of downstream kinases to inhibit the several pro-
apoptotic factors and mitochondrial permeability transition
pore (mPTP)’s opening at reperfusion, as illustrated in
Figure 2 [23, 38–44]. One of the downstream targets of
the RISK pathway is GSK-3β that plays important roles
in necrosis and apoptosis of cardiomyocytes [23]. GSK-3β
links to the regulation of a variety of cellular functions
includingglycogenmetabolism,geneexpression,andcellular
survival. Experimental studies have demonstrated that the
phosphorylation or inactivation of GSK-3β confers myocar-
dial protective eﬀects through its potential mitochondrial
eﬀects that include the inhibition of mPTP’s opening and
the control of mitochondrial adenine nucleotide transport
through the outer mitochondrial membrane [35–37]. The
mPTP is a nonselective large conductance channel in the
mitochondrial inner membrane, which is physiologically
closed. The mPTP remains closed during ischemia but
opens at the onset of reperfusion [45], and modulation
of the mPTP opening at early reperfusion can protect the
myocardium from reperfusion injury [46, 47].
Opening of mPTPs is involved in cell death induced by
a variety of causes, including ischemia/reperfusion, alcohol,
endotoxin, and anticancer agents [48]. In addition to
Ca2+, ROS and/or RNS-caused accumulation of inorganic
phosphate and depletion of ATP all can open mPTPs [49,
50]. It is also clear that all of these mPTP opening stimuli
are induced in cardiomyocytes subjected to long-sustained
ischemia/reperfusion. Ipost signiﬁcantly elevated the thresh-
old of mPTP’s opening in myocardial mitochondria [23].
TheinhibitionofmPTP’sopeningplaysacriticalendeﬀector
for the myocardial protective eﬀects of Ipost. Juhaszova et
al. [21] ﬁrst reported that GSK-3β activity is a determinant
of the threshold for mPTP’s opening in cardiomyocytes.
Therefore, GSK-3β plays a critical role in IPC- and Ipost-
mediated myocardial protection.
So far, there were two studies that have examined the
role of GSK-3β as an obligatory mediator of Ipost using
transgenic mice and showed diﬀerent results. Gomez et al.
[35] found that mice containing a mutant form of GSK-
3β (which cannot be phosphorylated and inhibited) were
resistant to the myocardial infarct-limiting eﬀects of Ipost
in situ, suggesting that GSK-3β inactivation is required
for Ipost’s myocardial protection. Contrast to the study of
Gomezet al.,Nishino et al. [51]h a v er e po rt edt h a tm i c ewi t h
am u t a n tf o r mo fb o t hG S K - 3 β and GSK-3α in which the
Akt phosphorylation sites were changed, thereby rendering
them to resistant to inactivation, were still amenable to the
myocardial infarct-limiting eﬀects of both IPC and Ipost.
This study suggests that GSK-3β and GSK-3α inactivation
are not necessary for myocardial protection in these settings.
Therefore, the exact role of GSK-3β in the setting of Ipost
remains further investigation, particularly under diﬀerent
conditions.
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Figure 2: Major signaling pathways of IPC- and Ipost-mediated
protection against cardiac cell death. Myocardial protection of
IPC and Ipost were proposed to be mediated by stimulation of
the prosurvival signaling pathway—PI3K/Akt pathway to inhibit
the GSK-3β activation either via PI3K pathway or JAK2/STAT3
pathway. Diabetes (DM) can inhibit the activation of STAT3 or Akt
toconsequentlyactivateGSK-3βthatinturninducesmitochondrial
cell death that is the critical cellular event for ischemia/reperfusion-
induced myocardial infarction.
3. Diabetic Inhibition of Ischemic
Preconditioning- andPostconditioning-
MediatedMyocardialProtectionagainst
Ischemia/Reperfusion Injury
Epidemiological data show that diabetes is a major risk
for cardiovascular morbidity and mortality [52, 53]. Coro-
nary artery diseases leading to myocardial infarction and
myocardium failure are one of the major chronic complica-
tions of diabetes, accounting for >75% of hospitalizations in
diabetic patients. The mortality rate of diabetic patients after
AMI is 2–6 folds higher than that of nondiabetic patients
[54, 55]. Increased mortality or increased myocardial injury
following AMI in diabetes is thought probably because of the
high prevalence of other risk factors, that is, hypertension,
hyperlipidemia, and advanced coronary artery diseases [56].
The poor prognosis may be also in part because of an
increaseinthemyocardialinjury inresponsetoischemiaand
reperfusion [57].
It is well known that insulin regulates metabolism in the
myocardium by modulating glucose transport, glycolysis,
glycogen synthesis, lipid metabolism, protein synthesis,4 Experimental Diabetes Research
growth, contractility, and apoptosis in cardiomyocytes [58,
59]. Myocardial insulin resistance develops in animal models
of both type 1 and type 2 diabetes [59]. These insulin-
stimulated eﬀects have been shown to be reduced in the
myocardium and cardiomyocytes of diabetic rats [60], which
may be the main reason for the increase in myocardial
injury in response to ischemia and reperfusion in diabetic
subjects.
In normal physiological status, insulin can regulate the
metabolism of glucose through PI3K/Akt pathway. Insulin
binds to its receptor and phosphorylates insulin receptor’s
substrates (IRS) such as IRS protein 1–4, Shc, Grb-2 asso-
ciated binder-1, and APS adapter protein. These substrates
have the SH2 structural domain and can provide the orienta-
tion sites for other signaling protein molecules, including the
downstream signaling molecules of PI3K [61, 62]. Activated
PI3K can phosphorylate the PI’s substrates speciﬁcally to
produce PIP2 and PIP3. PIP1 and PIP2 can translocate the
PI3K-dependent kinase (PDK1) and Akt from the cytoplasm
to plasma membrane. Under these conditions, Akt can be
phosphorylated at Thr308 and Ser473, and the activated Akt
then phosphorylates GSK-3β. The phosphorylation of GSK-
3β inactivates its activity, which will release its inhibition
of the synthesis of glycogen, as shown in Figure 2.T h e
activity of GSK-3β is two-fold higher in diabetes than that of
nondiabetes. Hyperglycemia and hyperinsulinemia can both
activate the GSK-3β [43, 44, 63]. The activated GSK-3β can
inhibit the myocardial transduction of insulin signaling and
the utilization of glucose through the phosphorylation of
IRS-1.
We have recently reported for the ﬁrst time that the
activation of GSK-3β played the pivotal role in diabetes-
induced energy disarrangement and consequently patholog-
ical remodeling in the myocardium [63]. This study suggests
that the activation of GSK-3β plays an important role in the
development of diabetic cardiomyopathy.
Diabetes is an independent risk factor for ischemic
myocardium disease; therefore, whether diabetes could
decrease the IPC and/or Ipost protection against ischemia/
reperfusion-induced myocardial damage has been ques-
tioned. Tosaki et al. found that IPC did not aﬀord protection
against ischemic damage in diabetic subjects [76]. Other
studies also showed that STZ-induced diabetes signiﬁ-
cantly aggravated myocardial ischemia/reperfusion injury
and blunted the protective eﬀects of IPC [77, 78]. However,
whether diabetes abrogates IPC- or Ipost-mediated myocar-
dial protection depends on IPC times or the periods of dia-
betes. For instance, Tsang et al. [15] discovered that in nor-
malWistarrats,one,two,andthreecyclesofIPCsigniﬁcantly
reduced infarct size induced by ischemia/reperfusion; how-
ever, in diabetic Goto-Kakizaki (GK) rats, only three cycles
of IPC reduced infarct size induced by ischemia/reperfusion,
compared with GK control hearts. Both one and two cycles
o fI P Cf a i l e dt oa ﬀord reductive eﬀect on the infarct,
suggesting that the diabetic heart has a high threshed to IPC
stimulus-induced myocardial protection. In addition, Shi-
Ting et al. [79] also showed that mice with diabetes for 4
weeks showed a tolerance to ischemia/reperfusion-induced
damage as compared to normal rats; IPC of these diabetic
mice remained aﬀording partial myocardial protection. In
contrast, mice with diabetes for 8 weeks showed a low
tolerance to ischemia/reperfusion damage as compared to
normal mice, and the IPC-induced myocardial protection
was not evident. These ﬁndings suggest that short-term dia-
betes makes the myocardium more tolerant, like an adaptive
response, but long-term diabetes makes the myocardium
more susceptible to ischemia/reperfusion-induced damage,
like a decompensated response.
Recently, Przyklenk et al. [80] have assessed the con-
sequences of a major risk factor—diabetes on the infarct-
sparing eﬀect of stuttered reﬂow using type 1 and type 2 dia-
betic mouse models. They gave the isolated buﬀer-perfused
myocardium for 30min ischemia, and the myocardium
received either standard reperfusion or three to six 10s cycles
of stuttered reﬂow as Ipost. They found that Ipost-reduced
infarct size via upregulation of extracellular signal-regulated
kinase 1/2 (ERK1/2) in normoglycemic mice, but diabetic
myocardium was refractory to Ipost-induced cardioprotec-
tion. They also found that in the type-1 diabetic model,
Ipost’s protective eﬀects were reversed by the restoration
of normoglycemia. Therefore, this study provided strong
evidence for a profound, but potentially reversible, defect
induced by diabetes in the myocardial protection of Ipost.
In a study by Drenger et al. [81], however, the protective
eﬀectsofIpostwerefoundtobeinhibitedinthediabetesrats,
and the diabetic inhibition of Ipost’s myocardial protection
was not relieved by insulin-induced normoglycemia. The
discrepancy between these two studies may be also due to
hyperglycemic times; as the hyperglycemic time increases,
the inhibited protective function of Ipost by diabetes may
become irreversible.
As the myocardial protection of IPC and Ipost is medi-
ated by a number of signaling pathways, the blunted myocar-
dial protection mediated by IPCindiabetes may be relatedto
the impairment in myocardial protective signaling pathways
such as the PI3K/Akt pathway, as illustrated in Figure 2 [2,
15,77].Sincesignaltransducerandactivatoroftranscription
(STAT) 3-mediated signaling pathway has been found to
play an important role in the cardiac protection induced
by IPC [14]a n dI p o s t[ 69]. Downregulation of STAT3
was found to be a causative of abolishment of the cardiac
protection mediated by IPC [17]a n dI p o s t[ 81–83]u n d e r
several conditions. Therefore, STAT3 downregulation may
be one of the mechanisms for diabetic inhibition of Ipost-
mediated cardiac protection, as discussed by Drenger et al.
[81]. Reportedly erythropoietin (EPO) has an IPC-like eﬀect
toshowmyocardialprotectionagainstischemia/reperfusion-
induced damage [73, 74]. However, Ghaboura et al. have
shown the attenuation of EPO-mediated myocardial protec-
tion under diabetic condition [43].
4.DiabeticActivationofGSK-3βPlaysaCritical
RoleinDiminishingIPC-andIpost-Mediated
MyocardialProtectiveFunction
In the above sections, we mentioned that there are several
signaling pathways that may involve in the myocardialExperimental Diabetes Research 5
Table 1: Potential candidates that may have protective eﬀect against ischemia reperfusion injury related with Akt/GSK-3β pathway.
Potential candidates Target of signaling pathway Reference
Lithium chloride GSK-3β inhibitor [44]
Indirubin-3 monooxime GSK-3β inhibitor [44]
SB216763 GSK-3β inhibitor [44]
Zinc Inactivation of GSK-3β directly or indirectly [42, 64–67]
Adenosine Activation/translocation of PKC, PI3K, and MAPK [68]
Endogenous opioids JAK-STAT pathway and then inactivation of GSK-3β [69–72]
Erythropoietin Activate Akt and inhibit GSK-3β [43, 73, 74]
Sevoﬂurane Phosphorylates Akt and then GSK-3β [75]
Except for the GSK-3β inhibitors, most of other potential candidates may exert their protective eﬀect against ischemia reperfusion injury through activation
of Akt and then inactivation of GSK-3β.
protection mediated by IPC or Ipost. As shown in Figure 2,
however, inactivation of GSK-3β has been considered as the
pivotal step for both IPC and Ipost’s myocardial protec-
tion. Furthermore, studies have demonstrated that diabetes-
induced activation of GSK-3β and impairment of RISK
play critical roles in diabetes-induced myocardial oxidative
damage and remodeling [43, 63]; other studies also reported
that the activity of GSK-3β is twice in diabetic patients
compared to that of nondiabetic patients [84]. Therefore,
whetherdiabeticactivationofGSK-3β bluntsIPCandIpost’s
myocardial protection really needs to be investigated [83, 85,
86].
Todate,studieshavedemonstratedadecreasedprotective
eﬀe c to fI P Co nA M Ii nd i a b e t i cs u b j e c t s[ 43, 44, 83, 85–
87]. It is clear that IPC produces myocardial protection
by phosphorylation of GSK-3β that inhibited the opening
of mPTP, but the activity of GSK-3β was found to be
elevated during diabetes [21, 23, 35, 63]. Yadav et al.
[44] investigated the role of GSK-3β in attenuating the
cardioprotective eﬀect of IPC using a type-1diabetic rat
model. They found that IPC had protective eﬀect on
normal rat myocardium, but this cardioprotective eﬀect
of IPC was signiﬁcantly attenuated in diabetic rat. At the
same time, they found that GSK-3β inhibitors, including
lithium chloride, indirubin-3 monooxime, and SB216763,
signiﬁcantly reduced the myocardial damage and decreased
infarct size in diabetic rat myocardium. This study suggests
that diabetes-induced attenuation of myocardial protection
mediated by IPC involves in the activation of GSK-3β.I n
addition, Ghaboura et al. [43] also demonstrated that the
attenuation of EPO-mediated myocardial protection from
ischemia/reperfusion under diabetic condition was related
to the decrease in EPO-stimulated GSK-3β phosphorylation.
The administration of GSK-3β inhibitor SB216763 protected
the hearts from ischemia/reperfusion-induced damage in
control and diabetic groups [43]. Therefore, the inhibition
of IPC myocardial protection in the diabetes is most likely
related to the activation of GSK-3β [43, 44].
Because Ipost and IPC share some common signal
transduction cascades proposed above (Figure 2), which
include the activation of survival protein kinase pathways
[13]. In the study by Drenger et al. [81], they demonstrated
that diabetes can impair the protective eﬀect of Ipost on
myocardial damage or infarction through inhibition of STAT
3-mediated PI3K/Akt pathways. Up to now, there remains
no proof to indicate that diabetes can inhibit the protective
eﬀect of Ipost on the myocardium; therefore, it remains to be
further explored.
5. Is ItPossible to Prevent
the DiabeticInhibition of IPC or
Ipost MyocardialProtectionagainst
Ischemia/Reperfusion Injury?
We have demonstrated that diabetes-induced myocardial
oxidative damage and inﬂammation mainly due to the
activation of GSK-3β. When we inactivated GSK-3β activ-
ity with its inactivator in diabetic mice, diabetes-induced
myocardial damage were almost completely prevented [63].
In addition, we have discussed above that inactivation
of GSK-3β with its speciﬁc inactivators can also directly
aﬀord the myocardial protection in diabetic animals treated
with GSK-3β inactivators [43, 44]. Therefore, any reagents
that can inactivate GSK-3β may have the potential to be
applied for the prevention of diabetic inhibition of IPC-
and/or Ipost-mediated myocardial protection. Except for the
consideration of GSK-3β inhibitors as discussed above and
alsolistedintheTable1,thefollowingreagents(Table1)ma y
also have such potential.
Zinc (Zn) is an interesting candidate because Zn is an
important trace element found in most body tissues as
bivalent cations and has essential roles in human health.
Zn has also an insulin-like function that was found also
to be related to its inactivation of GSK-3β [88]. We have
demonstrated that Zn supplementation to diabetic mice
could signiﬁcantly prevent the development of myocardial
oxidative damage, remodeling, and dysfunction in these
diabetic mice [64]. Although we did not explore whether
the myocardial protection by Zn supplementation in these
diabetic mice is mediated by the inactivation of GSK-3β
by supplied Zn, other studies have reported that Zn also
inactivated GSK-3β in several conditions. In the experiment
from Chanoit et al. [42], for instance, they found that the
treatment of myocardial H9c2 cells with ZnCl2(10μM) for
20min signiﬁcantly enhanced GSK-3β phosphorylation at6 Experimental Diabetes Research
Ser9, indicating that exogenous Zn can inactivate GSK-3β in
H9c2 cells. Other experiments [41] also demonstrated that
Zn also increased mitochondrial GSK-3β phosphorylation.
This may indicate an involvement of the mitochondria in the
action of Zn.
Zn applied at reperfusion period reduced cell death in
the cells subjected to ischemia/reperfusion, which conﬁrmed
t h a tZ nm a ya c ta sa ni n a c t i v a t o ro fG S K - 3 β to provide a
myocardial protection at reperfusion [41, 42, 89]. Besides
the direct inactivation of GSK-3β, Zn was also reported to
stimulate Akt phosphorylation by inhibiting Akt negative
regulators, including phosphatase and tensin homologue on
chromosome 10 (PTEN) and protein tyrosine phosphatase
1B (PTP1B) [65–67]. Inactivation of PTEN and/or PTP1B
may also contribute to Zn’s inactivation of GSK-3β via Akt
activation [41]. Therefore, Zn may inhibit GSK-3β by direct
and indirect mechanisms to protect the myocardium from
diabetic activation of GSK-3β-mediated pathogenic eﬀects.
In addition to Zn protective eﬀects, other substrates
are also reported to exert their protective eﬀect, as IPC
and Ipost, on ischemia/reperfusion-induced cardiac damage.
For instance, adenosine leads to the activation and/or
translocation of PKC, PI3K, and mitogen-activated protein
kinase (MAPK) and, subsequently, aﬀords IPC- or Ipost-
like myocardial protection at the level of mitochondrial
targets[68].Endogenousopioidshavealsobeendocumented
to be involved in protective eﬀects of Ipost [69, 70].
The administration of EPO at the time of reperfusion
aﬀorded a beneﬁcial eﬀect on Ipost myocardial protection
in rabbits [90]a n dm i c e[ 73]. EPO administration just
prior to reperfusion has reduced infarct size in isolated rat
and dog hearts, and even in canine hearts. Furthermore,
EPO administration even 5min after the reperfusion has
also provided protective responses [74, 91]. Lamont et al.
reported that both melatonin and resveratrol, as found in
red wine, protected the myocardium in an experimental
model from myocardial infarction via the survivor activating
factor enhancement pathway [92]. Fang et al. demonstrate
that sevoﬂurane administered immediately during early
reperfusion prevented the myocardial infarction [75].
Although all these substances can aﬀord myocardial
protective eﬀects on ischemia/reperfusion in the models
without diabetes, whether these substances can modify
diabetic individuals to maintain the myocardial protection
of IPC and Ipost remains to be explored in the future
studies.
6. Conclusion
Epidemiological data show that diabetes is a major risk
for cardiovascular diseases and the mortality of diabetic
patients with acute myocardial infarction is 2–6 folds higher
than that of nondiabetic patients with the same myocardial
infarction.Thepoorprognosismaybeatleastinpartbecause
of diabetic inhibition of IPC- and Ipost-mediated pro-
tective mechanisms against ischemia/reperfusion injuries.
Emerging evidence indicates that both IPC- and Ipost-
mediated myocardial protection predominantly be mediated
by stimulating PI3K/Akt and associated GSK-3β pathway
while diabetes-mediated pathogenic eﬀects are found to be
mediated by inhibiting PI3K/Akt and associated GSK-3β
pathway. Therefore, diabetic inhibition of IPC- and Ipost-
mediated myocardial protection may be mediated by the
activation of GSK-3β pathway, which suggests a possibility
that we may activate PI3K/Akt indirectly to inactivate GSK-
3β pathway or use GSK-3β inactivator directly to inactive
GSK-3β pathway to preserve IPC- and/or Ipost-mediated
myocardial protection under diabetic conditions. Although
there is not enough experimental and epidemiological
evidence to support our assumption, it was worthy to be
explored in the future studies.
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